Nectar Biopharma Private Limited, a member of the promoter group of Nureca Limited , disposed of 60,842 equity shares through an off-market transaction on June 09, 2026. The shares were transferred to promoter Saurabh Goyal for a total consideration of ₹1,43,70,880. This transaction resulted in a re-alignment of shareholding within the promoter and promoter group, while the aggregate holding remained unchanged at 68.09%.

The disclosure was submitted to BSE Limited and National Stock Exchange of India Limited pursuant to Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. Although the filing stated that the disclosure was not strictly required under specific SEBI circulars, it was made as a matter of abundant precaution. The company confirmed that the transaction does not impact the total promoter and promoter group holding in the company.

Shareholding Details

The following table details the changes in shareholding for the promoter and promoter group members following the inter se transfer:

Nishu Kansal, Company Secretary & Compliance Officer of Nureca Limited, signed the disclosure on behalf of the company. Saurabh Goyal, Director, signed the Form C disclosure confirming the transaction details.

Nureca Limited reported a net profit of ₹0.71 Cr for the financial year ended March 31, 2026, on total income from operations of ₹31.70 Cr. For the quarter ended March 31, 2026, the company recorded a net loss of ₹0.70 Cr on revenue of ₹31.70 Cr. The Board of Directors approved the audited financial results on May 29, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

The company’s earnings per share (EPS) for the year stood at ₹0.33, calculated on a face value of ₹10 per share. In Q4FY26, the EPS was (₹0.20). The full format of the audited financial results is available on the BSE website and the company's official website.

Board Decisions and Appointments

The Board approved an incremental capital expenditure of up to ₹128 Cr in plant and machinery for manufacturing additional medical devices, healthcare consumables, and hygiene products at its existing industrial land in Sundran, Dera Bassi, Punjab. The Board also approved the purchase of additional land adjoining the existing site for future expansion. This figure corrects a previous disclosure of ₹100 Cr due to a typographical error. M/s. MGSG and Associates were reappointed as Internal Auditor for FY26-27.

Mr. Naresh Gupta resigned as Chief Financial Officer and Key Managerial Personnel effective from the close of business hours on June 26, 2026, to pursue better career opportunities. Consequently, Mr. Chander Kant has been appointed as the new Chief Financial Officer effective June 27, 2026. Mr. Kant brings over 13 years of experience in finance and taxation.

Director Reappointments

The Board approved the reappointment of Mr. Aryan Goyal as Whole-time Director for a further period of three years w.e.f. May 28, 2027, and Mr. Saurabh Goyal as Managing Director for a further period of three years w.e.f. September 03, 2026. Both reappointments are subject to shareholder approval at the ensuing Annual General Meeting. Additionally, Ms. Smita Goyal was appointed as an Additional Director (Whole Time Director) for three years w.e.f. June 01, 2026, subject to shareholder approval.